|
[1]
|
Short, N.J., et al. (2017) Poor Outcomes Associated with +der(22)t(9;22) and -9/9p in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Receiving Chemotherapy plus a Tyrosine Kinase Inhibitor. American Journal of Hematology, 92, 238-243. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Schultz, K.R., et al. (2014) Long-Term Follow-Up of Imatinib in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Children’s Oncology Group Study AALL0031. Leukemia, 28, 1467-1471. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Levêque, D., Becker, G., Bilger, K., et al. (2020) Clinical Pharmacoki-netics and Pharmacodynamics of Dasatinib. Clinical Pharmacokinetics, 59, 1-8. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Crist, W.M., Carroll, A.J., Shuster, J., et al. (1990) Philadelphia Chromosome Positive Childhood Acute Lymphoblastic Leukemia: Clinical and Cytogenetic Characteristics and Treatment Outcome. A Pediatric Oncology Group Study. Blood, 76, 489-494. [Google Scholar] [CrossRef]
|
|
[5]
|
Kolenova, A., Maloney, K.W. and Hunger, S.P. (2016) Phila-delphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Crisis. Journal of Pediatric Hematology/Oncology, 38, e193. [Google Scholar] [CrossRef]
|
|
[6]
|
Heerema, N.A., Harbott, J., Galimberti, S., et al. (2004) Secondary Cytogenetic Aberrations in Childhood Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Are Nonrandom and May Be Associated with Outcome. Leukemia, 18, 693-702. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Arber, D.A., Orazi, A., Hasserjian, R., et al. (2016) The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia. Blood, 127, 2391. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Zhang, A., et al. (2016) Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in China: A Retrospective Study from the Chinese Childhood Cancer Group. Leukemia & Lymphoma, 57, 2696-2698.
|
|
[9]
|
薛玉娟, 陆爱东, 吴珺, 等. 酪氨酸激酶抑制剂联合化疗治疗儿童Ph阳性急性淋巴细胞白血病的分子学疗效与预后[J]. 中华实用儿科临床杂志, 2020, 35(3): 201-205.
|
|
[10]
|
Biondi, A., Schrappe, M., De Lorenzo, P., et al. (2012) Imatinib after Induction for Treatment of Children and Adolescents with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukaemia (EsPhALL): A Randomised, Open-Label, Intergroup Study. The Lancet Oncology, 13, 936-945. [Google Scholar] [CrossRef]
|
|
[11]
|
Raetz, E.A., Heerema, N.A., Siegel, M.J., et al. (2018) Dasatinib plus Intensive Chemotherapy in Children, Adolescents, and Young Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622. Journal of Clinical Oncology, 36, 2306-2313.
|
|
[12]
|
Shen, S., Chen, X., Cai, J., et al. (2020) Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncology, 6, 358-366. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Chen, M., Zhu, Y., Lin, Y., et al. (2021) Use of Tyrosine Kinase Inhibitors for Paediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia: A Systematic Review and Meta-Analysis. BMJ Open, 11, e42814. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Liu, J., Zhang, Y., Huang, H., et al. (2020) Recent Advances in Bcr-Abl Tyrosine Kinase Inhibitors for Overriding T315I Mutation. Chemical Biology & Drug Design, 97, 649-664. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Biondi, A., Gandemer, V., De Lorenzo, P., et al. (2018) Imatinib Treat-ment of Paediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia (EsPhALL2010): A Prospective, Intergroup, Open-Label, Single-Arm Clinical Trial. The Lancet Haematology, 5, e641-e652. [Google Scholar] [CrossRef]
|
|
[16]
|
Hunger, S.P., Saha, V., Devidas, M., et al. (2017) CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood, 130, 98. [Google Scholar] [CrossRef]
|
|
[17]
|
黄烽如, 刘连科, 钱依, 等. 酪氨酸激酶抑制剂的不良反应[J]. 药学与临床研究, 2022, 27(2): 108.
|
|
[18]
|
王天怡, 汤静燕, 李本尚. 酪氨酸激酶抑制剂在儿童Ph阳性急性淋巴细胞白血病的治疗进展[J]. 国际输血及血液学杂志, 2017, 40(4): 344-348.
|
|
[19]
|
Cortes, J.E., Saglio, G., Kantarjian, H.M., et al. (2016) Final 5-Year Study Results of DASISION: The Dasatinib versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology, 34, 2333-2340. [Google Scholar] [CrossRef]
|
|
[20]
|
傅维佳, 胡晓霞, 王丽炳, 等. 费城染色体阳性急性淋巴细胞白血病ABL激酶区突变的特征分析及其临床意义[J]. 中国临床医学, 2019, 26(5): 703-709.
|
|
[21]
|
Soverini, S., Bassan, R. and Lion, T. (2019) Treatment and Monitoring of Philadelphia Chromosome-Positive Leukemia Patients: Recent Advances and Remaining Challenges. Journal of Hematology & Oncology, 12, 39. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Zhao, X., Zhao, X., Chen, H., et al. (2018) Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation. Biology of Blood & Marrow Transplantation, 24, 1936-1943. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Kaczmarska, A., Liwa, P., Zawitkowska, J., et al. (2021) Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like—Recent Progress in Treatment. International Journal of Molecular Sciences, 22, 6411. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Chang, B.H., Willis, S.G., Stork, L., et al. (2012) Imatinib Resistant BCR-ABL1 Mutations at Relapse in Children with Ph+ ALL: A Children’s Oncology Group (COG) Study. British Journal of Haematology, 157, 507-510. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Bertrand, L.A.A.P. (2021) Therapeutic Approach and Outcome of Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia at First Relapse in the Era of Tyrosine Kinase Inhibitors: An SFCE Retrospective Study. Pediatric Blood & Cancer, 69, e29441.
|
|
[26]
|
沈垚佳, 主鸿鹄. 酪氨酸激酶抑制剂时代成人Ph染色体阳性急性淋巴细胞白血病的治疗进展[J]. 中华血液学杂志, 2020, 41(9): 779-782.
|
|
[27]
|
Papayannidis, C. and Martinelli, G. (2017) Blinatumomab in Ph+ B-ALL: Present and Perspectives. Oncotarget, 8, 93309-93310. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Millot, F., et al. (2020) Ponatinib in Childhood Philadelphia Chromosome-Positive Leukaemias: An International Registry of Childhood Chronic Myeloid Leukaemia Study. European Journal of Cancer, 136, 107-112. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Lindstrm, H. and Ran, F. (2020) The Effects of Combination Treatments on Drug Resistance in Chronic Myeloid Leukaemia: An Evaluation of the Tyrosine Kinase Inhibitors Axitinib and Asciminib. BMC Cancer, 20, 397. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Maude, S.L., Frey, N., Shaw, P.A., et al. (2014) Chimeric An-tigen Receptor T Cells for Sustained Remissions in Leukemia. The New England Journal of Medicine, 371, 1507-1517. [Google Scholar] [CrossRef]
|